HANNAH VANROOYEN: Open Payments
NPI 1497387518 · WINCHESTER, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,672 in 99 payments from 20 companies in 2025. Trend: 2023 $1,399 · 2024 $1,826 · 2025 $1,672
Food & beverage: $1,672
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $248 |
| Ardelyx, Inc. | 10 | $201 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $199 |
| Phathom Pharmaceuticals, Inc. | 20 | $193 |
| ABBVIE INC. | 13 | $187 |
| Regeneron Healthcare Solutions, Inc. | 5 | $110 |
| Ipsen Biopharmaceuticals, Inc | 4 | $103 |
| GENZYME CORPORATION | 3 | $87 |
| Gilead Sciences, Inc. | 4 | $83 |
| Janssen Biotech, Inc. | 2 | $42 |
Products named: XIFAXAN, IBSRELA, DUPIXENT, VOQUEZNA, ENTYVIO, IQIRVO, CREON, RINVOQ.
Industry payments across VA — which companies pay providers there.
